SCHEMBL4536703

SCHEMBL4536703

Oc1ccc(N2CCCC(O)C2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.44
RORC P51449 1/20 0.42
AR P10275 1/20 0.41
SMARCA2 P51531 1/20 0.41
SMARCA4 P51532 1/20 0.41
PBRM1 Q86U86 1/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
ESR2 Q92731 1/20 0.41
DEGS1 O15121 1/20 0.40
GAA P10253 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SMPD3 Q9NY59 3/20 0.40
SYK P43405 1/20 0.39
CCNE2 O96020 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7543878 0.89 AR (0.50) TDP1RORCARMAPTALDH1A1
SCHEMBL12082348 0.84 SMN1; SMN2 (0.50) RORCARMAPTALDH1A1KDM4E
SCHEMBL15651663 0.84 MAPT (0.53) TDP1RORCARSMARCA2SMARCA4
SCHEMBL17665074 0.84 SMN1; SMN2 (0.50) RORCARMAPTALDH1A1KDM4E
SCHEMBL15652154 0.84 MAPT (0.53) TDP1RORCARSMARCA2SMARCA4
SCHEMBL3027753 0.84 USP2 (0.42) RORCARSMARCA2SMARCA4PBRM1
SCHEMBL3027755 0.84 USP2 (0.42) RORCARSMARCA2SMARCA4PBRM1
SCHEMBL14637847 0.84 RORC (0.41) RORCARSMARCA2SMARCA4PBRM1
SCHEMBL2019193 0.84 MAPT (0.53) TDP1RORCARSMARCA2SMARCA4
SCHEMBL6628944 0.83 ALDH1A1 (0.53) RORCSMARCA2SMARCA4PBRM1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270380-A1 3,4,5-Substituted Piperidines as Renin Inhibitors NOVARTIS AG (CH) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270380-A1 3,4,5-Substituted Piperidines as Renin Inhibitors REN, AGTR1, AGTR2 TDP1 4500/4885RORC 4506/4885AR 2498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.